Skip to search formSkip to main contentSkip to account menu

Victrelis

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
  • C. Sheridan
  • Nature Biotechnology
  • 2014
  • Corpus ID: 205265039
The US Food and Drug Administration (FDA) approvals of Gilead’s Sovaldi (sofosbuvir) on December 6 and, to a lesser extent, of… 
2013
2013
The Hepatitis C virus infects an estimated 170 million people worldwide, and is the major cause of hepatitis, cirrhosis and liver… 
2012
2012
  • G. Sabourin
  • Perspective infirmiere : revue officielle de l…
  • 2012
  • Corpus ID: 2083703
Review
2012
Review
2012
  • Journal de pharmacie de Belgique
  • 2012
  • Corpus ID: 37026428
2011
2011
Merck & Co. and Roche, two rivals in the hepatitis C virus (HCV) market, have joined forces in a broad, non-exclusive… 
Highly Cited
2011
Highly Cited
2011
  • C. Sheridan
  • Nature Biotechnology
  • 2011
  • Corpus ID: 205269570
for people on Victrelis-based triple therapy. But the newly approved drugs also have major shortcomings, adding an extra safety… 
2011
2011
  • K. Garber
  • Nature Biotechnology
  • 2011
  • Corpus ID: 205276296
Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral… 
2011
2011
Chronic viral hepatitis B and C are a significant cause of chronic liver disease worldwide and still represent a pathology…